BLASUBCUTANEOUSINJECTABLE4 Generics Approved
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
64
Data completeness
6/8 — Strong
PROLIA (denosumab) by Amgen is rank ligand blocking activity [moa]. Approved for postmenopausal women with osteoporosis at high risk for fracture, defined, multiple risk factors for fracture and 3 more indications. First approved in 2010.
Drug data last refreshed 13h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROLIA (denosumab) is a monoclonal antibody that blocks RANK ligand, a key mediator of bone resorption. It is administered via subcutaneous injection and is indicated for osteoporosis and other bone loss conditions. The drug works by inhibiting osteoclast formation and survival, thereby reducing bone resorption and increasing bone mineral density. PROLIA represents a non-hormonal, biologic approach to bone health management and has become a cornerstone therapy in the osteoporosis treatment landscape since its 2010 FDA approval.
$0.7BPart D
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Worked on PROLIA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.